Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects

BACKGROUND: Lucerastat, an inhibitor of glucosylceramide synthase, has the potential to restore the balance between synthesis and degradation of glycosphingolipids in glycolipid storage disorders such as Gaucher disease and Fabry disease. The safety, tolerability, and pharmacokinetics of oral lucera...

Descripción completa

Detalles Bibliográficos
Autores principales: Guérard, N., Morand, O., Dingemanse, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237539/
https://www.ncbi.nlm.nih.gov/pubmed/28088251
http://dx.doi.org/10.1186/s13023-017-0565-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237539/
https://www.ncbi.nlm.nih.gov/pubmed/28088251
http://dx.doi.org/10.1186/s13023-017-0565-9

Ejemplares similares